Symphogen raises EUR 67.5 million
Danish biotech company Symphogen has once again raised a sizeable amount in support of its development activities. Two of its biggest shareholders have led the way.
BY BENJAMIN WERNER CHRISTENSEN
With a capital injection of EUR 67.5 million or more than half a billion DKK, the Danish-based biotech company Symphogen is ready to accelerated development of its most advanced candidate drug, Sym004.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Drug giant cancels partnership with Symphogen
For abonnenter
Drejer: Sad to see Santaris go, but…
For abonnenter
Drejer: The beginning of a new era
For abonnenter
